Abstract
Mixed dyslipidemia is a combination of elevated low-density lipoprotein cholesterol (LDL-C) with elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C), and may occur in some genetic disorders (familial hyperlipidemia, familial dysbetalipoproteinemia), diabetes, metabolic syndrome, or with drugs such as immunosuppressants or protease inhibitors. Patients with mixed dyslipidemia have increased triglyceride-rich remnant lipoproteins; because of the atherogenic and anti-atherogenic factors involved, more aggressive treatment with non-HDL-C as a target should be considered. However, according to the ATP IV expert panel (2013 ACC/AHA cholesterol guideline), no randomized controlled trial has shown evidence of treatment benefit for LDL-C and non-HDL-C targets. (The article has no abstract; this summary was written briefly from the introduction.)